Lv2
150 积分 2021-03-27 加入
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
1天前
已完结
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
1个月前
已完结
The current and emerging immunotherapy paradigm in small-cell lung cancer
2个月前
已完结
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
2个月前
已完结
Relationship between clinicopathological characteristics and PET/CT uptake in lung cancer: [18F]FAPI versus [18F]FDG
2个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
3个月前
已完结
The current and emerging immunotherapy paradigm in small-cell lung cancer
3个月前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
3个月前
已完结
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study
3个月前
已完结
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
4个月前
已完结
皖公网安备34019202002308
